Use of second-generation incretin analogs (GLP-1 and GIP receptor agonists) in type 1 diabetes and latent autoimmune diabetes in adults: A systematic review

The authors conducted a systematic review to evaluate the efficacy and potential benefits of second-generation incretin analogs, specifically semaglutide and tirzepatide, in treating type 1 diabetes (T1D) and latent autoimmune diabetes in adults (LADA). They identified 11 relevant studies, highlighting issues such as diagnostic challenges for LADA and the promising, though moderate-quality, evidence supporting the use of these medications in patients with residual beta-cell function. The review emphasizes the need for well-designed randomized trials to better understand the long-term effects of these treatments in clearly defined patient populations.